On October 8, 2010, the U.S. Food and Drug Administration (FDA) asked Abbott Laboratories to voluntarily withdraw from the U.S. market, its weight loss drug Meridia (sibutramine) because of clinical trial data indicating an increased risk of cardiovascular adverse events, including heart attack and stroke, in the studied population. Abbott has agreed to voluntarily stop marketing of Meridia in the United States.
The Center for Drug Evaluation and Research (CDER) at the FDA offers the following information on the use of drugs that have been potentially affected by fire, flooding or unsafe water and the use of temperature-sensitive drug products when refrigeration is temporarily unavailable.
FDA Approves Orphan Drug Status for Type 1 Diabetes Stem Cell Therapy
By Yael Waknine
Medscape Medical News
By Yael Waknine
Medscape Medical News
Audience: Pediatric and family practice healthcare professionals, public health professionals
FDA核准第一個可吸收之纖維素封劑（TachoSil）用於心血管手術
Audience: Pediatric and family practice healthcare professionals, public health professionals
By Yael Waknine
Medscape Medical News
就是中間那罐
On April 29, the FDA approved a 10-g pharmacy bulk vial of sterile vancomycin HCl injection (Hospira, Inc).
Audience: Neuropsychiatric healthcare professionals, other healthcare professionals, patients
[Posted 07/05/2007]
The U.S. Food and Drug Administration (FDA) today announced the approval of Neupro (rotigotine transdermal system), a skin patch designed to treat symptoms of early Parkinson's disease.
[Posted 03/16/2007] FDA notified healthcare professionals of new emerging safety concerns about Zyvox (linezolid) from a recent clinical study.
醫藥類 (14) 電腦知識 (3) 心情點滴 (3) 部落格摘要 (1) 其他知識 (1)
或請google "Mulicia"
